List of Tables
Table 1. Global Short-acting Recombinant Human Erythropoietin Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Short-acting Recombinant Human Erythropoietin Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Short-acting Recombinant Human Erythropoietin Drugs Market Competitive Situation by Manufacturers in 2024
Table 4. Global Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Short-acting Recombinant Human Erythropoietin Drugs Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Short-acting Recombinant Human Erythropoietin Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Short-acting Recombinant Human Erythropoietin Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Short-acting Recombinant Human Erythropoietin Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Short-acting Recombinant Human Erythropoietin Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Short-acting Recombinant Human Erythropoietin Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Short-acting Recombinant Human Erythropoietin Drugs as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Short-acting Recombinant Human Erythropoietin Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Short-acting Recombinant Human Erythropoietin Drugs Sales by Region (2020-2025) & (K Units)
Table 18. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Region (2020-2025)
Table 19. Global Short-acting Recombinant Human Erythropoietin Drugs Sales by Region (2026-2031) & (K Units)
Table 20. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Region (2026-2031)
Table 21. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Region (2020-2025)
Table 23. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Region (2026-2031)
Table 25. North America Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2020-2025) & (K Units)
Table 27. North America Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2026-2031) & (K Units)
Table 28. North America Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2020-2025) & (K Units)
Table 32. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2026-2031) & (K Units)
Table 33. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Short-acting Recombinant Human Erythropoietin Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Short-acting Recombinant Human Erythropoietin Drugs Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Short-acting Recombinant Human Erythropoietin Drugs Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Short-acting Recombinant Human Erythropoietin Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Short-acting Recombinant Human Erythropoietin Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units) by Type (2020-2025)
Table 51. Global Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units) by Type (2026-2031)
Table 52. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2020-2025)
Table 53. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2026-2031)
Table 54. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Type (2020-2025)
Table 57. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Type (2026-2031)
Table 58. Global Short-acting Recombinant Human Erythropoietin Drugs Price (US$/Unit) by Type (2020-2025)
Table 59. Global Short-acting Recombinant Human Erythropoietin Drugs Price (US$/Unit) by Type (2026-2031)
Table 60. Global Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units) by Application (2020-2025)
Table 61. Global Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units) by Application (2026-2031)
Table 62. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2020-2025)
Table 63. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2026-2031)
Table 64. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Application (2020-2025)
Table 67. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Application (2026-2031)
Table 68. Global Short-acting Recombinant Human Erythropoietin Drugs Price (US$/Unit) by Application (2020-2025)
Table 69. Global Short-acting Recombinant Human Erythropoietin Drugs Price (US$/Unit) by Application (2026-2031)
Table 70. Amgen Company Information
Table 71. Amgen Description and Business Overview
Table 72. Amgen Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Amgen Short-acting Recombinant Human Erythropoietin Drugs Product
Table 74. Amgen Recent Developments/Updates
Table 75. Johnson & Johnson Company Information
Table 76. Johnson & Johnson Description and Business Overview
Table 77. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Product
Table 79. Johnson & Johnson Recent Developments/Updates
Table 80. Roche Company Information
Table 81. Roche Description and Business Overview
Table 82. Roche Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Roche Short-acting Recombinant Human Erythropoietin Drugs Product
Table 84. Roche Recent Developments/Updates
Table 85. Kyowa Kirin Company Information
Table 86. Kyowa Kirin Description and Business Overview
Table 87. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Product
Table 89. Kyowa Kirin Recent Developments/Updates
Table 90. LG Chem Company Information
Table 91. LG Chem Description and Business Overview
Table 92. LG Chem Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. LG Chem Short-acting Recombinant Human Erythropoietin Drugs Product
Table 94. LG Chem Recent Developments/Updates
Table 95. Daewoong Pharmaceutical Company Information
Table 96. Daewoong Pharmaceutical Description and Business Overview
Table 97. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product
Table 99. Daewoong Pharmaceutical Recent Developments/Updates
Table 100. Wockhardt Company Information
Table 101. Wockhardt Description and Business Overview
Table 102. Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Product
Table 104. Wockhardt Recent Developments/Updates
Table 105. CJ Healthcare Company Information
Table 106. CJ Healthcare Description and Business Overview
Table 107. CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Product
Table 109. CJ Healthcare Recent Developments/Updates
Table 110. 3SBio Company Information
Table 111. 3SBio Description and Business Overview
Table 112. 3SBio Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. 3SBio Short-acting Recombinant Human Erythropoietin Drugs Product
Table 114. 3SBio Recent Developments/Updates
Table 115. Kexing Biopharm Company Information
Table 116. Kexing Biopharm Description and Business Overview
Table 117. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Product
Table 119. Kexing Biopharm Recent Developments/Updates
Table 120. Harbin Pharmaceutical Group Company Information
Table 121. Harbin Pharmaceutical Group Description and Business Overview
Table 122. Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Product
Table 124. Harbin Pharmaceutical Group Recent Developments/Updates
Table 125. Beijing Four Rings Bio-Pharmaceutical Company Information
Table 126. Beijing Four Rings Bio-Pharmaceutical Description and Business Overview
Table 127. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product
Table 129. Beijing Four Rings Bio-Pharmaceutical Recent Developments/Updates
Table 130. Key Raw Materials Lists
Table 131. Raw Materials Key Suppliers Lists
Table 132. Short-acting Recombinant Human Erythropoietin Drugs Distributors List
Table 133. Short-acting Recombinant Human Erythropoietin Drugs Customers List
Table 134. Short-acting Recombinant Human Erythropoietin Drugs Market Trends
Table 135. Short-acting Recombinant Human Erythropoietin Drugs Market Drivers
Table 136. Short-acting Recombinant Human Erythropoietin Drugs Market Challenges
Table 137. Short-acting Recombinant Human Erythropoietin Drugs Market Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
Table 141. Authors List of This Report
List of Figures
Figure 1. Product Picture of Short-acting Recombinant Human Erythropoietin Drugs
Figure 2. Global Short-acting Recombinant Human Erythropoietin Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Short-acting Recombinant Human Erythropoietin Drugs Market Share by Type: 2024 & 2031
Figure 4. Epoetin-alfa Product Picture
Figure 5. Epoetin-beta Product Picture
Figure 6. Darbepoetin-alfa Product Picture
Figure 7. Others Product Picture
Figure 8. Global Short-acting Recombinant Human Erythropoietin Drugs Market Value by Application (2020-2031) & (US$ Million)
Figure 9. Global Short-acting Recombinant Human Erythropoietin Drugs Market Share by Application: 2024 & 2031
Figure 10. Anemia
Figure 11. Kidney Disorders
Figure 12. Others
Figure 13. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Short-acting Recombinant Human Erythropoietin Drugs Market Size (2020-2031) & (US$ Million)
Figure 15. Global Short-acting Recombinant Human Erythropoietin Drugs Sales (2020-2031) & (K Units)
Figure 16. Global Short-acting Recombinant Human Erythropoietin Drugs Average Price (US$/Unit) & (2020-2031)
Figure 17. Short-acting Recombinant Human Erythropoietin Drugs Report Years Considered
Figure 18. Short-acting Recombinant Human Erythropoietin Drugs Sales Share by Manufacturers in 2024
Figure 19. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Share by Manufacturers in 2024
Figure 20. Global 5 and 10 Largest Short-acting Recombinant Human Erythropoietin Drugs Players: Market Share by Revenue in Short-acting Recombinant Human Erythropoietin Drugs in 2024
Figure 21. Short-acting Recombinant Human Erythropoietin Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 22. Global Short-acting Recombinant Human Erythropoietin Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 23. North America Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country (2020-2031)
Figure 24. North America Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country (2020-2031)
Figure 25. United States Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Canada Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 27. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country (2020-2031)
Figure 28. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country (2020-2031)
Figure 29. Germany Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. France Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. U.K. Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Italy Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Russia Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Asia Pacific Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Region (2020-2031)
Figure 35. Asia Pacific Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Region (2020-2031)
Figure 36. China Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. Japan Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. South Korea Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. India Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Australia Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. China Taiwan Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Southeast Asia Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Latin America Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country (2020-2031)
Figure 44. Latin America Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country (2020-2031)
Figure 45. Mexico Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Brazil Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Argentina Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Middle East and Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country (2020-2031)
Figure 49. Middle East and Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country (2020-2031)
Figure 50. Turkey Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Saudi Arabia Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. UAE Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Global Sales Market Share of Short-acting Recombinant Human Erythropoietin Drugs by Type (2020-2031)
Figure 54. Global Revenue Market Share of Short-acting Recombinant Human Erythropoietin Drugs by Type (2020-2031)
Figure 55. Global Short-acting Recombinant Human Erythropoietin Drugs Price (US$/Unit) by Type (2020-2031)
Figure 56. Global Sales Market Share of Short-acting Recombinant Human Erythropoietin Drugs by Application (2020-2031)
Figure 57. Global Revenue Market Share of Short-acting Recombinant Human Erythropoietin Drugs by Application (2020-2031)
Figure 58. Global Short-acting Recombinant Human Erythropoietin Drugs Price (US$/Unit) by Application (2020-2031)
Figure 59. Short-acting Recombinant Human Erythropoietin Drugs Value Chain
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
